

Corporate Office: 402, Raghava Ratna Towers,

Chirag Ali Lane, Hyderabad - 500 001. Telangana (INDIA)

Ph.: 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in

GSTIN: 36AACCS8220M1Z4 CIN: L24230TG1994PLC018786

Date: 30.05.2022

Head Listing & Compliance Metropolitan Stock Exchange of India Limited 205(A), 2nd floor, Piramal Agastya Corporate Park, Kamani Junction, LBS Road, Kurla (West), Mumbai – 400070.

Dear Sir,

Sub: Outcome of the Board Meeting held today i.e., on 30th May, 2022 - Reg.

Pursuant to Regulation 33 and Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors at its Meeting held today i.e., on Monday, 30th May, 2022 had inter-alia considered and approved the Audited Financial Results for the Quarter & Year ended 31st March, 2022. Accordingly, please find enclosed herewith the following:

- 1. Statement of Audited Financial results for the quarter & year ended 31st March, 2022.
- 2. The Audit Report by M/s. Niranjan & Narayan, Chartered Accountants Hyderabad, Statutory Auditors of the Company on the financial results for the quarter and year ended 31st March, 2022.
- 3. Declaration on unmodified opinion on the Auditor's Report with respect to the Audited Financial Results of the Company for the quarter and financial year ended 31st March, 2022.

Kindly take the above on your records.

Thanking you,

Yours faithfully, For Sigachi Laboratories Limited

(B. Kumar)
Chief Financial Officer

The meeting Commenced at 4: 00 PM
The Meeting Concluded at 6:10 PM

Regd.Office: S.No: 530 & 534, Bonthapally - 502 313, Gummadidala Mandal, Sanga Reddy District, Telangana.

Tel No.: 040 - 23204230 / 23204273

Website:www.slllab.com, Email:sigachilaboratories@yahoo.co.in

CIN:L24230TG1994PLC018786

Statement of Audited Financial Results For The Quarter and Year Ended 31st March, 2022

(Rs. In Lakhs)

			Quarter ended		Year e	nded
Sl.No	Particulars	31.03.2022	31.12.2021	31.03.2021	31.03.2022	31.03.2021
		Audited	Un Audited	Audited	Audited	Audited
1	Revenue from operations	39.28	44.27	78.32	259.68	347.61
2	Other income	14.30	14.53	15.32	44.10	38.09
3	Total Income (1+2)	53.58	58.80	93.64	303.78	385.70
4	Expenses					
	a) Cost of materials consumed	-	-	-	-	-
	b) Purchase of Stock-in-Trade	-	-	-	-	-
	c) Change in Inventories	-	-	-	-	-
	d) Employee benefits expense	9.73	8.39	9.59	34.16	28.97
	e) Finance costs	-	-	-	-	-
	f) Depreciation and amortization expense	4.24	4.23	4.14	16.82	16.58
	g) Other expenses	5.24	3.14	19.64	15.41	26.50
	Total Expenses	19.21	15.76	33.37	66.39	72.05
5	Profit/(Loss) before exceptional items and tax (3-4)	34.37	43.04	60.27	237.39	313.65
	Exceptional Items	-	-	-	-	-
7	Proft/(Loss) before tax (5-6)	34.37	43.04	60.27	237.39	313.65
8	Tax expense					
	(a) Current tax	13.29	11.21	13.55	39.66	39.88
	(b) Deferred tax	(1.00)	(0.65)	-	(1.91)	(1.64)
	Total Tax Expense	12.29	10.56	13.55	37.75	38.24
9	Profit/(Loss) for the Period (7-8)	22.08	32.48	46.72	199.64	275.41
10	Other Comprehensive income (OCI)					
	(a) Items that will not be reclassified to profit or loss	(45.68)	(25.90)	30.66	98.03	414.42
	(b) Remeasurement gains/(losses) on defined benefit plans	(0.16)	-	0.03	(0.16)	0.03
	Tax on Items that will not be reclassified to profit or loss	0.04	-	(0.01)	0.04	(0.01)
	(c) Items that will be reclassified to profit or loss	-	-	-	-	-
	Total Other Comprehensive income	(45.80)	(25.90)	30.68	97.91	414.44
	Total Comprehensive income (9+10)	(23.72)	6.58	77.40	297.55	689.85
11	Paid-up Equity Share Capital (Face Value Rs. 10/- per share)	675.31	675.31	675.31	675.31	675.31
12	Other Equity	-	-	-	2,243.74	1,946.19
13	Earnings per equity share (of Rs.10/- each) (not annualized) (in Rs.)					
	(1) Basic	0.33	0.48	0.69	2.96	4.08
	(2) Diluted	0.33	0.48	0.69	2.96	4.08

(Rs.in Lakhs)

		Quarter ended			Year ended	
Sl.No	Particulars	31.03.2022	31.12.2021	31.03.2021	31.03.2022	31.03.2021
		Audited	Un Audited	Audited	Audited	Audited
1	Segment Revenue					
II.	a) Bulk Drugs and Intermediates (Lease Rents)	42.00	30.50	40.00	122.50	116.50
	b) Investments	11.58	28.30	53.64	181.28	269.20
	Total	53.58	58.80	93.64	303.78	385.70
	Less: Inter Segment Revenue	-	-	-	-	-
	Net sales/Income from Operations	53.58	58.80	93.64	303.78	385.70
2	Segment Results Profit/ (Loss) before tax and finance Costs from each segment					
	a) Bulk Drugs and Intermediates (Lease Rents)	37.24	26.10	35.35	104.25	98.56
	b) Investments	11.58	28.30	53.64	181.28	269.20
	Total	48.82	54.40	88.99	285.53	367.76
	Less: (i) Finance Costs	-	-	-		-
	(ii) Other Un-allocable Expenditure net off	14.45	11.36	28.72	48.14	54.11
	(iii) Un-allocable income	-	-	-	-	-
	Total Profit Before Tax	34.37	43.04	60.27	237.39	313.65
3	Capital Employed					
	(Segment Assets – Segment Liabilities)					
	a) Bulk Drugs and Intermediates	641.33	619.55	620.95	641.33	620.95
	b) Investments	2,333.46	2,378.96	2,056.29	2,333.46	2,056.29
	Total	2,974.79	2,998.51	2,677.24	2,974.79	2,677.24

Notes:

- The above Financial results have been reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their respective Meetings held on 30th May, 2022. The above Financial Results have been subjected to Ind AS compliant review by the statutory auditors. These financial resultls are also available on the website of Metropolitan Stock Exchange of India Limited (www.msei.in) and also on the website of the Company (www.slllab.com).
- The figures for the quarter ended 31st March, 2022 and 31st March, 2021 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published year to date figures upto the third quarter of the respective financial year which were subjected to limited review.
- 3 Previous year/period figures have been recasted/regrouped/reclassified wherever necessary to make them comparable with current year/period figures.

By Order of the Board for SIGACHI LABORATORIES LIMITED

Place: Hyderabad Date: 30.05.2022 (T.R.Sekhar) Executive Director DIN:02943146

Regd.Office: S.No: 530 & 534, Bonthapally - 502 313. Gummadidala Mandal, Sanga Reddy District, Telangana.

Tel No.: 040 - 23204230 / 23204273

Website:www.slllab.com, Email:sigachilaboratories@yahoo.co.in CIN:L24230TG1994PLC018786

Statement of Assets and Liabilities as at 31st March, 2022.

(Rs. In Lakhs)					
Particulars	As at 31.03.2022	As at 31.03.2021			
	Audited	Audited			
A. ASSETS					
1. Non-Current Assets					
(a) Property Plant and Equipment	228.58	245.79			
(b) Financial Assets					
(i) Investments	2,111.72	1,887.13			
(ii) Other Financial Assets	43.74	43.53			
(c) Other non Current Assets	286.01	-			
Total Non - Current Assets	2,670.05	2,176.45			
2. Current Assets					
(a) Financial Assets					
(i) Investments	39.73	38.39			
(ii) Trade Receivables	15.89	-			
(iii) Cash and Cash Equivalents	80.66	242.97			
(iv) Other Financial Assets	221.75	169.16			
(b) Other Current Assets		111.18			
Total Current Assets	358.03	561.70			
Total Assets	3,028.08	2,738.15			
B. EQUITY AND LIABILITIES					
1. Equity					
(a) Equity Share Capital	731.06	731.06			
(b) Other Equity	2,243.73	1,946.18			
Total Equity	2,974.79	2,677.24			
2. Liabilities					
Non-Current Liabilities					
(a) Financial Liabilities	_	_			
(b) Long term Provisions	5.88	<u> </u>			
(c) Deferred Tax Liabilities (net)	15.72	17.68			
(d) Other non - Current Liabilities	25.00	25.00			
Total Non - Current Liabilities	46.60	42.68			
Total Tvoil - Current Elabilities	40.00	42.00			
Current Liabilities					
(a) Financial Liabilities					
(i) Borrowings	-	-			
(ii) Trade Payables	-	-			
(iii) Other Financial Liabilities	6.69	13.94			
(b) Provisions	-	4.29			
(c) Other Current Liabilities		-			
Total Current Liabilities	6.69	18.23			
Total Equity and Liabilities	3,028.08	2,738.15			

for SIGACHI LABORATORIES LIMITED

(T.R.Sekhar) Executive Director DIN:02943146

Place: Hyderabad Date: 30.05.2022

Cash Flow Statement For The Year Ended 31.03.2022

(Rs. in Lakhs)

		(Rs. in Lakhs)
Particulars	Year Ended	Year Ended
	31.03.2022	31.03.2021
Cash Flows from Operating Activities		
Profit before tax	237.39	313.65
Adjustments for:		
Depreciation and amortization expense	16.82	16.58
Dividend Received	(33.25)	(28.13)
Provision for Gratuity & Leave Encashment	1.43	2.35
(Profit)/Loss on Sale of Plant and Equipment	(0.46)	-
Bad Deposits Recovery	(0.16)	-
Bad Debts Recovery	(0.88)	-
Loss due to floods to Compound wall	0.02	=
Interest Received	(63.85)	(69.69)
Fair Value (Gains)/Losses	(82.68)	(171.39)
Operating profit before working capital changes	74.38	63.37
Movements in Working Capital		
(Increase)/Decrease in Trade Receivables	(15.89)	20.85
(Increase)/Decrease in Other Current Financial Assets	(52.59)	3.13
(Increase)/Decrease in Other Non Current Financial Assets	(0.21)	-
(Increase)/Decrease in Other Current Assets	111.19	(35.13)
(Increase)/Decrease in Other Non Current Assets	(286.01)	-
Increase/(Decrease) in Other Financial Liabilities	(9.21)	0.97
Changes in Working Capital	(252.72)	(10.18)
Cash generated from operations	(178.34)	53.19
Direct Taxes Paid	37.72	38.10
Net Cash from Operating Activities (A)	(216.06)	15.09
Cash flows from Investing Activities	(4, 55)	(5.74)
(Purchase) of Property, Plant & Equipment	(1.63)	(0.71)
Insurance Claim received	1.97	- (50.40)
(Purchase)/Sale of Investments (Net Aggregate)	(124.27)	(60.48)
Dividend Received	33.25	28.13
Bad Deposits Recovery	0.16	=
Bad Debts Recovery	0.89	-
Proceeds from sale of Plant and Equipment	0.48	-
Interest Received	63.85	69.69
(Increase)/Decrease in other term deposits	79.05	(18.92)
Net Cash used in Investing Activities (B)	53.75	17.71
Cash Flows from/(used in) Financing Activities		
Proceeds from Long term borrowings		<u>-</u>
Repayment/(Proceeds) of/from Short-term borrowings	_	_
Dividend paid	_	<u>-</u>
Net Cash used in Financing Activities (C)	-	-
Net Increase/(Decrease) in Cash and Cash Equivalents (A+B+C)	(162.31)	32.80
Cash and Cash Equivalents at the beginning of the year	242.97	210.17
Cash and Cash Equivalents at the beginning of the year Cash and Cash Equivalents at the ending of the year	80.66	210.17 242.97
Cash and Cash Equivalents at the chang of the year	80.00	242.37

for SIGACHI LABORATORIES LIMITED

Place : Hyderabad Executive Director
Date : 30.05.2022 DIN:02943146

niranjan & narayan Chartered Accountants

Chartered Accounta

GSTIN: 36AACFN0604K1ZJ

first floor, h.no: 7-1-28/1/A/21 shyamkaran road, ameerpet hyderabad - 500016 tel: 040-29806074

email: caniranjan@yahoo.com

www.nncas.com

INDEPENDENT AUDITOR'S REPORT

To The Board of Directors, Sigachi Laboratories Limited

FRN : 005899S

Report on the audit of the Financial Results

Opinion

We have audited the accompanying quarterly financial results of Sigachi Laboratories Limited (the company) for the quarter ended 31st March, 2022 and the year to date results for the period from 1st April, 2021 to 31st March, 2022, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the financial results:

i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and


ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information for the quarter ended 31st March, 2022 as well as the year to date results for the period from 1st April, 2021 to 31st March, 2022.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Financial Results

These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, prescribed under Section 133 of the Act read with relevant rules issued there under and other accounting principles generally accepted in



India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.


The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Results

Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial results, whether due to
 fraud or error, design and perform audit procedures responsive to those risks, and obtain audit
 evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not
 detecting a material misstatement resulting from fraud is higher than for one resulting from error,
 as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override
 of internal control.
- Obtain an understanding of internal financial control relevant to the audit in order to design audit
 procedures that are appropriate in the circumstances, but not for the purpose of expressing an
 opinion on the effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial results, including the
 disclosures, and whether the financial results represent the underlying transactions and events in
 a manner that achieves fair presentation.



We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

The statement includes the results for the quarter ended March 31, 2022 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2022 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations.

FRN: 005899 Hyderabad

Date: 30.05.2022

Place: Hyderabad

For Niranjan and Narayan Chartered Accountants (Firm Registration No.005899S)

> M. Nilanjan Partner

Membership No. 029552 UDIN: 22029552AJWCGZ7362



Corporate Office: 402, Raghava Ratna Towers,

Chirag Ali Lane, Hyderabad - 500 001. Telangana (INDIA)

Ph.: 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in

GSTIN: 36AACCS8220M1Z4 CIN: L24230TG1994PLC018786

Date: 30.05.2022

Head Listing & Compliance Metropolitan Stock Exchange of India Limited 205(A), 2nd floor, Piramal Agastya Corporate Park, Kamani Junction, LBS Road, Kurla (West), Mumbai - 400070.

Dear Sir,

Re: Declaration relating to the Unmodified Opinion by Statutory Auditors' on the Audited Financial Statements for the Quarter and Year ended 31st March, 2022 - Reg.

Pursuant to Regulation 33(3) (d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to declare and confirm that the Statutory Auditors of the Company, M/s. Niranjan Narayan, Chartered Accountants (Firm Registration no. 05899S) have issued their Audit Report with unmodified opinion on the Audited Financial Results of the Company for the quarter and financial year ended 31st March, 2022.

This Declaration is issued in compliance of Regulation 33(3)(d) of the SEBI (LODR) Regulations, 2015 as amended vide its circular no CIR/CFD/CMD/56/2016 dated 27 May, 2016.

Please take the above declaration on record.

Thanking you,

Yours faithfully, For Sigachi Laboratories Limited

> (T. Raja Sekhar) Whole Time Director DIN: 02943146